Haemonetics Corp
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Haemonetics Corp
119.18
+1.70%
vs ±10.3% implied · ×0.17
shaded = implied · ▲▼ = realized
Haemonetics has 1 disclosed supplier and 8 disclosed customers in SEC filings.
SentenceIn fiscal 2026, one Plasma customer accounted for approximately 13% of total net revenues.
basisHAE FY2026 revenue $1.3B
HAE 10-Kaccession 0000313143-26-000050
SentenceIn addition, we manufacture our vascular closure devices under a shelter plan service agreement with Offshore International Incorporated (d/b/a Tetakawi) pursuant to which we lease our manufacturing facility in Guaymas, Mexico.
HAE 10-Kaccession 0000313143-25-000025
SentenceOver the last 20 years, the collection of source plasma has increasingly been performed by vertically integrated biopharmaceutical companies such as Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary and CSL Limited (together with its affiliates, "CSL").
SentenceOver the last 20 years, the collection of source plasma has increasingly been performed by vertically integrated biopharmaceutical companies such as Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary and CSL Limited (together with its affiliates, "CSL").
SentenceOur Blood Center business supports the collection of plasma for blood collectors, such as the American Red Cross, using apheresis collection devices.
HAE 10-Kaccession 0000313143-26-000050
SentenceThis revenue decrease was primarily driven by lower sales volumes in North America relating to the previously announced customer transition of CSL Plasma, partially offset by share gains, higher volume and pricing benefits.
HAE 10-Kaccession 0000313143-26-000050
SentenceOn January 13, 2025, we completed the transaction with GVS for total cash consideration of up to $65.8 million, which includes $43.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones.
HAE 10-Kaccession 0000313143-25-000025
SentenceOver the last 20 years, the collection of source plasma has increasingly been performed by vertically integrated biopharmaceutical companies such as Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary and CSL Limited (together with its affiliates, "CSL").
HAE 10-Kaccession 0000313143-26-000050
SentenceOver the last 20 years, the collection of source plasma has increasingly been performed by vertically integrated biopharmaceutical companies such as Grifols S.A., Octapharma AG, Takeda's BioLife Plasma subsidiary and CSL Limited (together with its affiliates, "CSL").
HAE 10-Kaccession 0000313143-26-000050
Expected move
Inputs8Q avg ±11.7%·×0.70·cheap
straddle ±9.7%
spot 119.65exp Nov 20ATM strike 120ATM straddle 13.65IV 60%